Stryker Available For Sale Securities Debt Securities Current decreased by 2.2% to $87.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.2%, from $89.00M to $87.00M. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows relatively stable performance with a 1.9% CAGR.
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
current_assets_available_for_sale_securities_debt_securi_87ec82| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $84.00M | $76.00M | $75.00M | $72.00M | $83.00M | $77.00M | $84.00M | $86.00M | $77.00M | $76.00M | $82.00M | $77.00M | $83.00M | $84.00M | $91.00M | $89.00M | $89.00M | $87.00M | $89.00M | $87.00M |
| QoQ Change | — | -9.5% | -1.3% | -4.0% | +15.3% | -7.2% | +9.1% | +2.4% | -10.5% | -1.3% | +7.9% | -6.1% | +7.8% | +1.2% | +8.3% | -2.2% | +0.0% | -2.2% | +2.3% | -2.2% |
| YoY Change | — | — | — | — | -1.2% | +1.3% | +12.0% | +19.4% | -7.2% | -1.3% | -2.4% | -10.5% | +7.8% | +10.5% | +11.0% | +15.6% | +7.2% | +3.6% | -2.2% | -2.2% |